A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

NCT06669975 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: AP402 (Part 1 Dose esclation)
DRUG: AP402 (Part 2 Dose Expansion)

Sponsor

AP Biosciences Inc.